IPO India
Latest news, explainers and analysis on IPO India. Tracking 5 stories on Arth Vani.
Connected in the graph
Latest on IPO India
IPOBreakingBonfiglioli Transmissions IPO: What High-Risk Investors Should Know
Bonfiglioli Transmissions, an Indian subsidiary of the Italian Bonfiglioli Group, is reportedly planning an Initial Public Offering (IPO). This move could offer high-risk investors an opportunity to participate in the company's growth, though specific details like price band and issue dates are yet to be announced.
IPOBreakingAcevector (Snapdeal) IPO: Investors Await Official Details on Potential Listing
Acevector, the parent company of e-commerce platform Snapdeal, is a subject of investor interest regarding a potential Initial Public Offering (IPO). While discussions around its prospective market debut are circulating, specific details like IPO dates, price band, and issue size are yet to be officially announced.
IPOBreakingMolbio Diagnostics IPO Opens Today: Analysts See Value, GMP at 15%
The Initial Public Offering (IPO) for Molbio Diagnostics opened today, with market analysts recommending subscription. The company's valuations are noted to be in line with industry benchmarks and offered at a discount to its listed peers' average P/E multiple of 64.9x. The Grey Market Premium (GMP) for the issue is reported at 15%.
IPOBreakingDhoot Transmission Launches ₹3,067 Crore IPO; GMP Signals 30% Listing Gain
Dhoot Transmission has initiated its Initial Public Offering (IPO) valued at ₹3,067 crore, combining a fresh issue of shares and an Offer for Sale (OFS). Early market indications suggest potential listing gains of up to 30%. Key details regarding the IPO's price band and subscription dates are yet to be announced.
IPOBreakingMolbio Diagnostics Plans ₹940 Crore IPO, Includes ₹200 Crore Fresh Issue for Capex
Molbio Diagnostics is set to launch an Initial Public Offering (IPO) to raise a total of ₹940 crore. The IPO comprises a fresh issuance of shares worth ₹200 crore, earmarked for capital expenditures, and an offer for sale (OFS) of ₹740 crore by promoters. The company, known for its tuberculosis diagnostic kits, operates globally across more than ninety countries.
IPO investments are subject to market risk and allotment. Read the RHP / prospectus before applying; grey-market premium (GMP) is unofficial and unreliable. Some listings may be sponsored. Not investment advice.